medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number 04

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (04)

Invasive mola in 13-year-old girl. Fundamental aspects in diagnosis and treatment

Frías-Sánchez Z, Melero-Cortés LM, Merchán-Felipe MI, Vieites Pérez-Quintela MB, Calderón-Cabrera AM, González-Cejudo C, Martínez-Maestre MÁ

Language: Spanish
References: 20
Page: 252-260
PDF size: 433.74 Kb.


ABSTRACT

Background: Gestational trophoblastic neoplasia is a rare tumor that originates from pregnancy and it develop from anormal proliferation of trophoblastic tissue. It includes four varieties, including invasive mole and choriocarcinoma. They can present different degrees of proliferation, being essential differential diagnosis since it directly influences the treatment. Premalignant moles are usually treated by suction curettage while malignant forms require systemic therapy with mono or polychemotherapy.
Objective: Report the case, paying special attention to the differential diagnosis and treatment used, analyzing the reasons why polychemotherapy is established and describing the different possible options, based on current scientific evidence.
Clinical case: We present the case of an invasive mola in a 13-year-old patient hospitalized by vomiting and abdominal pain. During this period, complementary techniques such as the determination of the β fraction of the human chorionic gonadotropin (β-hCG) or computed tomography (CT) are required to establish the differential diagnosis. Finally, the definitive diagnosis is provided by the biopsy obtained by curettage. Treatment is instituted with the pattern of polychemotherapy being, currently, with complete remission of the disease.
Conclusions: Thus, it is essential to detect anomalous gestation early, to understand perfectly the evolution of this entity, the importance of contraception during its resolution, and to minimize patients susceptible to chemotherapy.


REFERENCES

  1. Ning F, Hou H, Morse AN, Lash GE. Understanding and management of gestational trophoblastic disease. F1000Res. 2019: 10; 8. doi: 10.12688/f1000research.14953.

  2. Stevens FT, Katzorke N, Tempfer C, Kreimer U, Bizjak GI, Fleisch MC, Fehm TN. Gestational Trophoblastic Disorders: An uptodate in 2015. GebFra Science. 2015:1043-1050.

  3. Li X, Xu Y, Liu Y, Cheng X, Wang X, Lu W, Xie X. The management of hydatidiform mole with lung nodule: a retrospective analysis in 53 patients. J Gynecol Oncol. 2019; 30(2):e16. doi: 10.3802/jgo.2019.30.e16.

  4. Braga A, Mora P, de Melo AC, Nogueira-Rodrigues A, Amim-Junior J, Rezende-Filho J, Seckl MJ. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide. World J Clin Oncol. 2019; 10(2):28- 37. doi:10.5306/wjco.v10.i2.28.

  5. Martínez Camilo RV. Mola invasiva. Revista Cubana de Obstetricia y Ginecología. 2016; 42(3):366-371.

  6. Hilario de la Rosa J, Rui Wamba MJ, Usandizaga JM. Mola invasora y abdomen agudo: a propósito de un caso. Clin Invest Gin Obst. 2002; 29(3): 110-113.

  7. Bermúdez AJ, Cortés C, Díaz LE, Crane C, Ching R, Aragón M et al. Estudio bioquímico y genético de la enfermedad trofoblástica gestacional. Medicina. 2005; 28(1):14-18.

  8. Wu X, Zhu J, Zhao A. Ovarian hyperstimulation syndrome in a spontaneous pregnancy with invasive mole. J Obstet Gynaecol Res. 2015; 41(5): 817-22. doi: 10.1111/jog.12606.

  9. Harvey RA. Las diferencias analíticas en inmunoensayo de la gonadotropina coriónica humana y la habilidad para medir la gonadotropina coriónica humana en los tumores de la enfermedad trofoblástica gestacional y de la célula germinal. J Reprod Med. 2010; 55(7-8): 285-295.

  10. Disoebrata D. El tipo Invasivo: La perspectiva indonesia. J Reprod Med. 2007; 52(9):839-42.

  11. Okumura KM. La apariencia “Sonographic” de un tipo adelantado del invasivo y el asociado trombo meta estático en la vena cava inferior. J Clin. 2013; 41(2): 113-5.

  12. Shaaban AM, Rezvani M, Haroun RR, Kennedy AM, Elsayes KM, Olpin JD, Salama ME, Foster BR, Menias CO. Gestational Trophoblastic Disease: Clinical and Imaging Features. Radiographics. 2017; 37(2):681-700. doi: 10.1148/ rg.2017160140.

  13. Denny L, Quinn M. FIGO cáncer report 2015. Int J Gynaecol Obstet 2015;131 (2): s75.

  14. Rodabaugh KJ, Bernstein MR, Goldstein DP, et al.: Natural history of postterm choriocarcinoma. J Reprod Med. 1998; 43(1): 75–80.

  15. Braga A, Biscaro A, do Amaral Giordani JM, Viggiano M, Elias KM, Berkowitz RS, Seckl MJ. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? Eur J Obstet Gynecol Reprod Biol. 2018; 223:50-55. doi: 10.1016/j. ejogrb.2018.02.001.

  16. FIGO Oncology Commitee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet. 2002; 77:293-7.

  17. Wang Q, Fu J, Hu L, et al.: Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017; 9: CD007289.

  18. Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi39-50.

  19. Bolze PA, Attia J, Massardier J, Seckl MJ, Massuger L, van Trommel N, et al. Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. Eur J Cancer 2015; 51:1725-31.

  20. Ring AM. The concept of benign metastasizing hydatidiform moles. Am J Clin Pathol 1972; 58:111-7.




2020     |     www.medigraphic.com